Press release
Global the Cancer Monoclonal Antibody Market to Hit USD 93.5 Billion, Globally By 2030 at 6.8% CAGR | Infinium Global Research
To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/1234
Market Overview and Growth Projection
The Cancer Monoclonal Antibody Market, valued at USD 51.2 billion in 2022, is projected to ascend to USD 93.5 billion by 2030, exhibiting a commendable Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period from 2023 to 2030.
Revolutionizing Cancer Treatment with Precision Therapies
The market for cancer monoclonal antibodies is centered around the creation and deployment of diverse cancer treatments. Monoclonal antibodies, a specialized form of targeted drug therapy, operate by identifying and targeting specific proteins within cancer cells, inhibiting their growth and preventing future proliferation. This precision approach is recognized as a form of immunotherapy, fostering the body's ability to combat cancer cells more effectively.
Market Drivers and Expanding Demand
The increasing prevalence of cancer worldwide is a primary catalyst driving market expansion. Monoclonal antibodies offer innovative and efficient treatment options for various cancer types, catering to the rising demand within the market. These antibodies, recognized for their precision in therapy, reduce harm to healthy cells and minimize side effects compared to conventional treatments like chemotherapy.
Challenges and Opportunities in Cancer Monoclonal Antibody Market
While the high costs associated with development and administration present obstacles to market growth, the field of personalized medicine presents significant growth opportunities. Advances in genomics and personalized medicine allow for customized monoclonal antibody therapies, enhancing treatment efficacy based on individual genetic and molecular characteristics.
Market Dynamics and Regional Insights
The North American market dominates the Cancer Monoclonal Antibody Market due to a growing geriatric population and an increase in cancer cases. The U.S. pharmaceutical market leads in innovation, boosting medicine manufacturing. Additionally, increased spending on R&D has led to innovations in cancer monoclonal antibodies and diagnosis technologies, further propelling market expansion.
Market Segments Detailed in the Report
The report segments the global Cancer Monoclonal Antibody Market based on antibody type (murine, chimeric, humanized), application (blood cancer, breast cancer, lung cancer, others), and end-users (hospitals, clinics, research and academic institutes/laboratories).
Profiles of Key Market Players
The report features detailed profiles of major industry players, including Genentech, Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Novartis AG, Par Pharmaceutical, CELGENE CORPORATION, Merck & Co., Inc., Bristol-Myers Squibb Company, Roche Holding AG, and AstraZeneca, offering insights into their strategies and market positioning.
Enquire Here Get Customization & Check the Discount for the Report @ https://www.infiniumglobalresearch.com/market-reports/customization/1234
Table of Content
Chapter 1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
Chapter 2. Executive Summary
2.1. Cancer Monoclonal Antibody Market Highlights
2.2. Cancer Monoclonal Antibody Market Projection
2.3. Cancer Monoclonal Antibody Market Regional Highlights
Chapter 3. Global Cancer Monoclonal Antibody Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter`s Five Forces Analysis
3.4. IGR-Growth Matrix Analysis
3.4.1. IGR-Growth Matrix Analysis by Antibody Type
3.4.2. IGR-Growth Matrix Analysis by Application
3.4.3. IGR-Growth Matrix Analysis by End User
3.4.4. IGR-Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Cancer Monoclonal Antibody Market
Chapter 4. Cancer Monoclonal Antibody Market Macro Indicator Analysis
Chapter 5. Company Profiles and Competitive Landscape
5.1. Competitive Landscape in the Global Cancer Monoclonal Antibody Market
5.2. Companies Profiles
5.2.1. Genentech, Inc.
5.2.2. Dr. Reddy's Laboratories Ltd.
5.2.3. Eli Lilly and Company
5.2.4. Novartis AG
5.2.5. Par Pharmaceutical
5.2.6. CELGENE CORPORATION
5.2.7. Merck & Co., Inc.
5.2.8. Bristol-Myers Squibb Company
5.2.9. Roche Holding AG
5.2.10. AstraZeneca
Chapter 6. Global Cancer Monoclonal Antibody Market by Antibody Type
6.1. Murine
6.2. Chimeric
6.3. Humanized
Chapter 7. Global Cancer Monoclonal Antibody Market by Application
7.1. Blood Cancer
7.2. Breast Cancer
7.3. Lung Cancer
7.4. Others
Chapter 8. Global Cancer Monoclonal Antibody Market by End User
8.1. Hospitals and Clinics
8.2. Research and Academic Institute/Laboratories
Chapter 9. Global Cancer Monoclonal Antibody Market by Region 2023-2030
9.1. North America
9.1.1. North America Cancer Monoclonal Antibody Market by Antibody Type
9.1.2. North America Cancer Monoclonal Antibody Market by Application
9.1.3. North America Cancer Monoclonal Antibody Market by End User
9.1.4. North America Cancer Monoclonal Antibody Market by Country
9.1.4.1. The U.S. Cancer Monoclonal Antibody Market
9.1.4.1.1. The U.S. Cancer Monoclonal Antibody Market by Antibody Type
9.1.4.1.2. The U.S. Cancer Monoclonal Antibody Market by Application
9.1.4.1.3. The U.S. Cancer Monoclonal Antibody Market by End User
9.1.4.2. Canada Cancer Monoclonal Antibody Market
9.1.4.2.1. Canada Cancer Monoclonal Antibody Market by Antibody Type
9.1.4.2.2. Canada Cancer Monoclonal Antibody Market by Application
9.1.4.2.3. Canada Cancer Monoclonal Antibody Market by End User
9.1.4.3. Mexico Cancer Monoclonal Antibody Market
9.1.4.3.1. Mexico Cancer Monoclonal Antibody Market by Antibody Type
9.1.4.3.2. Mexico Cancer Monoclonal Antibody Market by Application
9.1.4.3.3. Mexico Cancer Monoclonal Antibody Market by End User
9.2. Europe
9.2.1. Europe Cancer Monoclonal Antibody Market by Antibody Type
9.2.2. Europe Cancer Monoclonal Antibody Market by Application
9.2.3. Europe Cancer Monoclonal Antibody Market by End User
9.2.4. Europe Cancer Monoclonal Antibody Market by Country
9.2.4.1. Germany Cancer Monoclonal Antibody Market
9.2.4.1.1. Germany Cancer Monoclonal Antibody Market by Antibody Type
9.2.4.1.2. Germany Cancer Monoclonal Antibody Market by Application
9.2.4.1.3. Germany Cancer Monoclonal Antibody Market by End User
9.2.4.2. United Kingdom Cancer Monoclonal Antibody Market
9.2.4.2.1. United Kingdom Cancer Monoclonal Antibody Market by Antibody Type
9.2.4.2.2. United Kingdom Cancer Monoclonal Antibody Market by Application
9.2.4.2.3. United Kingdom Cancer Monoclonal Antibody Market by End User
9.2.4.3. France Cancer Monoclonal Antibody Market
9.2.4.3.1. France Cancer Monoclonal Antibody Market by Antibody Type
9.2.4.3.2. France Cancer Monoclonal Antibody Market by Application
9.2.4.3.3. France Cancer Monoclonal Antibody Market by End User
9.2.4.4. Italy Cancer Monoclonal Antibody Market
9.2.4.4.1. Italy Cancer Monoclonal Antibody Market by Antibody Type
9.2.4.4.2. Italy Cancer Monoclonal Antibody Market by Application
9.2.4.4.3. Italy Cancer Monoclonal Antibody Market by End User
9.2.4.5. Rest of Europe Cancer Monoclonal Antibody Market
9.2.4.5.1. Rest of Europe Cancer Monoclonal Antibody Market by Antibody Type
9.2.4.5.2. Rest of Europe Cancer Monoclonal Antibody Market by Application
9.2.4.5.3. Rest of Europe Cancer Monoclonal Antibody Market by End User
9.3. Asia Pacific
9.3.1. Asia Pacific Cancer Monoclonal Antibody Market by Antibody Type
9.3.2. Asia Pacific Cancer Monoclonal Antibody Market by Application
9.3.3. Asia Pacific Cancer Monoclonal Antibody Market by End User
9.3.4. Asia Pacific Cancer Monoclonal Antibody Market by Country
9.3.4.1. China Cancer Monoclonal Antibody Market
9.3.4.1.1. China Cancer Monoclonal Antibody Market by Antibody Type
9.3.4.1.2. China Cancer Monoclonal Antibody Market by Application
9.3.4.1.3. China Cancer Monoclonal Antibody Market by End User
9.3.4.2. Japan Cancer Monoclonal Antibody Market
9.3.4.2.1. Japan Cancer Monoclonal Antibody Market by Antibody Type
9.3.4.2.2. Japan Cancer Monoclonal Antibody Market by Application
9.3.4.2.3. Japan Cancer Monoclonal Antibody Market by End User
9.3.4.3. India Cancer Monoclonal Antibody Market
9.3.4.3.1. India Cancer Monoclonal Antibody Market by Antibody Type
9.3.4.3.2. India Cancer Monoclonal Antibody Market by Application
9.3.4.3.3. India Cancer Monoclonal Antibody Market by End User
9.3.4.4. South Korea Cancer Monoclonal Antibody Market
9.3.4.4.1. South Korea Cancer Monoclonal Antibody Market by Antibody Type
9.3.4.4.2. South Korea Cancer Monoclonal Antibody Market by Application
9.3.4.4.3. South Korea Cancer Monoclonal Antibody Market by End User
9.3.4.5. Australia Cancer Monoclonal Antibody Market
9.3.4.5.1. Australia Cancer Monoclonal Antibody Market by Antibody Type
9.3.4.5.2. Australia Cancer Monoclonal Antibody Market by Application
9.3.4.5.3. Australia Cancer Monoclonal Antibody Market by End User
9.3.4.6. Rest of Asia-Pacific Cancer Monoclonal Antibody Market
9.3.4.6.1. Rest of Asia-Pacific Cancer Monoclonal Antibody Market by Antibody Type
9.3.4.6.2. Rest of Asia-Pacific Cancer Monoclonal Antibody Market by Application
9.3.4.6.3. Rest of Asia-Pacific Cancer Monoclonal Antibody Market by End User
9.4. RoW
9.4.1. RoW Cancer Monoclonal Antibody Market by Antibody Type
9.4.2. RoW Cancer Monoclonal Antibody Market by Application
9.4.3. RoW Cancer Monoclonal Antibody Market by End User
9.4.4. RoW Cancer Monoclonal Antibody Market by Sub-region
9.4.4.1. Latin America Cancer Monoclonal Antibody Market
9.4.4.1.1. Latin America Cancer Monoclonal Antibody Market by Antibody Type
9.4.4.1.2. Latin America Cancer Monoclonal Antibody Market by Application
9.4.4.1.3. Latin America Cancer Monoclonal Antibody Market by End User
9.4.4.2. Middle East Cancer Monoclonal Antibody Market
9.4.4.2.1. Middle East Cancer Monoclonal Antibody Market by Antibody Type
9.4.4.2.2. Middle East Cancer Monoclonal Antibody Market by Application
9.4.4.2.3. Middle East Cancer Monoclonal Antibody Market by End User
9.4.4.3. Africa Cancer Monoclonal Antibody Market
9.4.4.3.1. Africa Cancer Monoclonal Antibody Market by Antibody Type
9.4.4.3.2. Africa Cancer Monoclonal Antibody Market by Application
9.4.4.3.3. Africa Cancer Monoclonal Antibody Market by End User
More Insights on this report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/market-reports/enquiry/1234
Reasons to Buy this Report:
=> Comprehensive analysis of global as well as regional markets of Cancer Monoclonal Antibody.
=> Complete coverage of all the product types and application segments to analyze the trends, developments, and forecast of market size up to 2030.
=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company.
=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand, and/or diversify.
2nd Floor, Ganadish Empire, Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027
About Infinium Global Research:
Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes, and non-profit/non-government organizations to meet their knowledge and information needs.
Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations, and the environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global the Cancer Monoclonal Antibody Market to Hit USD 93.5 Billion, Globally By 2030 at 6.8% CAGR | Infinium Global Research here
News-ID: 3302361 • Views: …
More Releases from Infinium Global Research LLP
Infinium Global Research LLP Launches Comprehensive Service to Assist Foreign Co …
Pune, India - October 26, 2024 - Infinium Global Research LLP is excited to announce the launch of a dedicated service aimed at providing end-to-end support for foreign companies entering or expanding within the Indian market. With a strategic network of partnerships with top legal and consulting firms and increased presence across key Indian cities, Infinium is well-equipped to facilitate smooth market entry, operational setup, and business expansion for international…
Global Sterilization Services Market Size Worth USD 12.55 Billion By 2030 | CAGR …
Infinium Global Research, a leading provider of market intelligence, has recently launched an in-depth report on the Global Sterilization Services Market, offering comprehensive analysis and detailed insights into its segments and market trends.
The comprehensive study explores the impact of various factors such as drivers, restraints, and macro indicators on both the global and regional sterilization services market, providing crucial forecasts and dollar value projections.
To Know More Request a Sample of…
Global Proprotein Convertase Subtilisin/Kexin Type 9 Market is Projected to Surp …
Infinium Global Research introduces a detailed analysis of the global and regional Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) market, providing an extensive study of its segments, trends, forecasts, and dollar values in their latest report. This comprehensive study empowers stakeholders in the pharmaceutical and healthcare sectors with invaluable insights into this burgeoning market.
To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/420
Market Insight:
The global Proprotein Convertase Subtilisin/Kexin Type 9 market,…
Global Neuromodulation Market is Anticipated to Reach USD 7.27 Billion and Growi …
Infinium Global Research, a pioneering market intelligence firm, introduces a comprehensive report delving into the Global Neuromodulation Market, providing extensive analysis and in-depth exploration of its segments, market trends, and projections.
To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/93
Market Insight:
The global neuromodulation market, valued at USD 3.51 Billion in 2022, is poised to ascend to USD 7.27 Billion by 2030, exhibiting a noteworthy CAGR of 9.59% during the forecast…
More Releases for Antibody
Evolving Market Trends In The Antibody Drug Conjugates Industry: Regulation On A …
The Antibody Drug Conjugates Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Antibody Drug Conjugates Market Size During the Forecast Period?
The market size for antibody drug conjugates has experienced rapid expansion in the past few years. It's projected to rise from…
TIGIT Antibody Clinical Trials FDA Approval Market Size Anti TGIT Antibody Sales …
Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028 Report Highlights:
• Anti TIGIT Antibodies In Clinical Trials: > 50 Antibodies
• First Anti TIGIT Antibody To Get Approval Within Next 5 Years
• Global Anti TIGIT Antibodies Clinical Pipeline Insight By Company, Indication and Phase
• Insight On More Than 50 Anti TIGIT Antibodies In Clinical Trials
• Anti TIGIT Antibodies Market Trends by Indication & Country
• Global Anti TIGIT Antibodies Market Dynamics
Download Report:
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
In recent years, the global…
Mammalian Polyclonal IgG Antibody Market, Mammalian Polyclonal IgG Antibody Mark …
"According to the research report, the global inspection machines market was valued at USD 845.21 million in 2022 and is expected to reach USD 1,437.59 million by 2032, to grow at a CAGR of 5.5% during the forecast period."
Request Our Free Sample Report for Inspection Machines Market Insights and Emerging Trends @ https://www.polarismarketresearch.com/industry-analysis/inspection-machines-market/request-for-sample
Report Overview
Polaris Market Research, a leading global market research and consulting company, has recently published its latest report…
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
The combination antibody therapy market is expected to experience significant growth in the coming years. Combination antibody therapy involves the use of two or more monoclonal antibodies (mAbs) in combination to treat various diseases, such as cancer, autoimmune disorders, and infectious diseases.
Request For Free Sample Report of "Combination Antibody Therapy Market"@ https://www.persistencemarketresearch.com/samples/11740
Combination antibody therapy has several potential benefits over single-agent therapies, including increased efficacy, improved patient outcomes, and reduced toxicity.…
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
Combination antibody therapy involves the use of two or more antibodies to target and treat a specific disease or condition. This type of therapy is often used in cancer treatment, as it can be more effective at targeting and killing cancer cells than single-antibody therapies. Combination antibody therapy can also be used to treat a range of other diseases and conditions, including autoimmune diseases, infectious diseases, and allergic conditions.
Request For…
Procalcitonin Antibody Market Report 2018: Segmentation by Type (Polyclonal Proc …
Global Procalcitonin Antibody market research report provides company profile for Ningbo Medicalsystem Biotechnology, Snibe, Vazyme Biotech, Getein Biotech, Hotgen Biotech, Lumigenex, Shanghai Medicine'nest Pharmaceutical, Thermo Fisher, Roche Diagnostics, bioMerieux, HyTest, Wondfo and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for…
